Abstract:Abstract Abstract 2908 Objectives This study was to detect if there were abnormalities of membrane hemopoietic cytokine receptor expression on CD34+ bone marrow cells in MDS. Methods 34 newly diagnosed MDS(12 in low-risk and 22 in high-risk) cases and 32 normal controls were enrolled in this study. Their CD34+CD38+ and CD34+CD38- bone marrow cells and the expressions of stem cell factor receptor(SCF-R),erythropoietin receptor (EpoR), granulocyte colony-stimulating factor receptor (G-CSFR) and thrombopoietin receptor (TpoR) on those cells were measured by flow cytometry. Results The mean percentage of CD34+ BMMNCs of MDS cases in high risk[(2.94±4.79)%)] was significantly higher than that of control group[(0.95±1.06)%](P<0.05). The mean percentages of CD34+CD38+ cells were significantly lower in low risk and high risk groups[(86.98±6.83)% and (83.57±9.86)% respectively] than that in control group [(92.41±3.43)%], thus the percentage of CD34+CD38- cells was significantly higher in either low-risk or high-risk group[(13.03±6.84)% and (16.42±9.85)% respectively]than that in control group[(7.59±3.43)%](P<0.05). In control group, the mean percentage of antigen expression of EpoR was significantly lower in CD34+CD38+ cells [(17.72±20.24) %] than that in CD34+CD38- cells [(64.65±21.02)%](P<0.01), The expressions of SCF-R,G-CSFR and TpoR on CD34+CD38- cells were not significantly different from these on CD34+CD38+ cells. The expression of EpoR on CD34+CD38+ cells of low-risk and high-risk MDS groups[(7.01±6.82)% and (7.16±9.45)% respectively] were significantly lower than that of control group[(17.72±20. 24) %] (P<0.05), The expression of G-CSFR on CD34+CD38+ cells of low-risk and high-risk MDS groups[(22.65±12.14)% and (26.50±19.65)% respectively] were significantly lower than that of control group[(45.13±23.41)%](P<0.01). The amount of EpoR on CD34+CD38-cells of low-risk and high-risk MDS groups[(40.18±20.38)% and (28.58±17.00)% respectively] were significantly lower than that of control group[(64.65±21.02)%](P<0.01), The expression of TpoR on CD34+CD38- cells of low-risk and high-risk MDS groups[(4.46±7.45)% and (3.23±4.55)% respectively] were significantly lower than that of control group[(15.33±14.95)%](P<0.01). The incidence of cytopenia of MDS cases with low expression rates of hemopoietic cytokine receptors on CD34+cells were higher than that of MDS with high expression rates of hemopoietic cytokine receptors. Conclusions There were abnormalities of differentiation and membrane hemopoietic cytokine receptors expression of CD34+ bone marrow cells in MDS, which were associated with MDS cytopenia and might be useful for MDS diagnosis. Disclosures: No relevant conflicts of interest to declare.

Analysis of the immunophenotype features of bone marrow cells of patients with myelodysplatic syndromes

Immunophenotyping in Myelodysplastic Syndromes

Cytogenetic Abnormalities Predict Disease Progression in Primary Myelodysplastic Syndrome: A Multicentric Study in 508 Chinese Patients.

Analysis of the Karyotype Abnormalities and Its Prognostic in 298 Patients with Myelodysplastic Syndrome

Evaluation of the Clinical Significance of Immunophenotyping in Myelodysplastic Syndrome.

[Karyotype Analysis of 283 Cases of Myelodysplastic Syndrome].

Immunophenotypic Features of Myelodysplastic Syndromes by CD45/SSC Gating and Flow Cytometry

Analysis of Immunophenotypes in Patients with Leukemia and Myelodysplastic Syndrome by Direct Immunofluoresence

Expression and significance of CD34, CD117 on bone marrow mononuclear cells of patients with myelodysplastic syndrome

Clinical analysis for thirty patients with myelodysplastic syndromes

Differentiation and expression of membrane hemopoietic cytokine receptors on CD34+ bone marrow cells in patients with myelodysplastic syndromes

[Evaluation of the Subsets of Lymphocytes and Their Activated Status in Patients with Myelodysplastic Syndrome].

Gene Expression Profiling of the Bone Marrow Mononuclear Cells from Patients with Myelodysplastic Syndrome

Clinical Analysis of Myelodysplastic Syndrome

[Research Advances in Value of Flow Cytometric Immunophenotyping in Diagnosis and Prognostic Evaluation of Myelodysplastic Syndrome].

Immunophenotyping Characteristics of AML and Their Correlation with the Curative Effects

Study on the Membrane Hemopoietic Cytokine Receptor Expression on Cd34+Bone Marrow Cells of the Patients with Myelodysplastic Syndromes

Flow cytometric scoring system (FCMSS) assisted diagnosis of myelodysplastic syndromes (MDS) and the biological significance of FCMSS-based immunophenotypes: FCMSS-assisted Diagnosis of MDS

[Expression of CD133 in the Bone Marrow of Patients with Myelodysplastic Syndrome and Its Clinical Significance].

Expression and Significance of CD117 in Bone Marrow of Patients with Myelodysplastic Syndrome

Expression and Clinical Significance of CD38 and CD133 in Myelodysplastic Syndrome